Table 5.
Response of the primary site and the neck metastatic nodes in patients treated with NACT + IMRT + CCRT vs NACT + IMRT
| Primary site | Neck | Primary site + neck | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| NACT + IMRT(n=36) | NACT +IMRT + CCRT (n=89) | P-valuea | NACT + IMRT(n=36) | NACT +IMRT + CCRT (n=89) | P-valuea | NACT + IMRT(n=36) | NACT + IMRT +CCRT(n=89) | P-valuea | |
|
| |||||||||
| RR (CR + PR) | 34 (94.4%) | 84 (94.4%) | 0.68 | 35 (97.2%) | 85 (95.5%) | 1.00 | 33 (91.7%) | 83 (93.3%) | 1.00 |
| CR | 26 (72.2%) | 67 (75.3%) | 0.82 | 30 (83.3%) | 70 (78.7%) | 0.63 | 24 (66.7%) | 64 (71.9%) | 0.67 |
| PR | 8 (22.2%) | 17 (19.1%) | 0.81 | 5 (13.9%) | 15 (16.8%) | 0.79 | 9 (25.0%) | 19 (21.4%) | 0.81 |
| SD | 2 (5.6%) | 5 (5.6%) | 0.68 | 1 (2.8%) | 4 (4.5%) | 1.00 | 3 (8.3%) | 6 (6.7%) | 1.00 |
| PD | 0 | 0 | - | 0 | 0 | - | 0 | 0 | – |
Note:
a
Two-sided chi-squared test.
Abbreviations: NACT, neoadjuvant chemotherapy; IMRT, intensity modulated radiotherapy; CCRT, concurrent chemotherapy; RR, response rate; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.